Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Regulus Therapeutics Inc.

    NASDAQ: RGLS · Real-Time Price · USD
    8.16
    0.02 (0.25%)
    At close: Jun 24, 2025, 3:59 PM
    8.05
    -1.41%
    After-hours: Jun 24, 2025, 07:42 PM EDT
    0.25%
    Bid 5.87
    Market Cap 565.3M
    Revenue (ttm) n/a
    Net Income (ttm) -47.52M
    EPS (ttm) -0.68
    PE Ratio (ttm) -12.01
    Forward PE -7.68
    Analyst Hold
    Ask 10.44
    Volume 6,810,825
    Avg. Volume (20D) 2,553,608
    Open 8.15
    Previous Close 8.14
    Day's Range 8.07 - 8.17
    52-Week Range 0.83 - 8.35
    Beta 0.37

    About RGLS

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol RGLS
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for RGLS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    +136.8%
    Regulus Therapeutics shares are trading higher aft... Unlock content with Pro Subscription
    3 months ago
    +16.28%
    Regulus Therapeutics shares are trading higher after the company announced topline results from the phase 1b MAD study of Farabursen for autosomal dominant polycystic kidney disease.
    news image

    1 month ago · businesswire.com

    REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS

    NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...

    news image

    1 month ago · benzinga.com

    Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher

    U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Wednesday.

    news image

    1 month ago · benzinga.com

    Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million

    Novartis AG NVS agreed to acquire Regulus Therapeutics Inc.  RGLS on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion.

    news image

    1 month ago · businesswire.com

    RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders

    NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Regulus Therapeutics Inc. (NASDAQ: RGLS) to Novartis AG in cash is fair to Regulus shareh...

    news image

    1 month ago · businesswire.com

    Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders

    MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Regulus (Nasdaq: RGLS) for possible breaches of fiduciary duty and other violations of law in its transaction with Novartis. Click here to l...

    news image

    1 month ago · reuters.com

    Novartis to buy Regulus Therapeutics for up to $1.7 billion

    Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain access to its experimental kidney disease drug, the California-based drug developer said on Wednesday.

    news image

    2 months ago · zacks.com

    Should You Buy Regulus (RGLS) After Golden Cross?

    Regulus Therapeutics Inc. (RGLS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, RGLS's 50-day simple moving average broke out above...

    news image

    2 months ago · benzinga.com

    Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease

    Regulus Therapeutics Inc. RGLS released topline results from all patients in the fourth cohort in its Phase 1b MAD study of farabursen (RGLS8429) autosomal dominant polycystic kidney disease (ADPKD) o...

    Add to Watchlist